Management of recalcitrant hidradenitis suppurativa with ustekinumab

Acta Dermato-Venereologica

Volumn 92, Issue 3, 2012, Pages 320-321

  Sharon, Victoria R ^a   Garcia, Miki Shirakawa ^a   Bagheri, Sepideh ^a   Goodarzi, Heidi ^a   Yang, Clara ^a   Ono, Yoko ^a   Maverakis, Emanual ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Northern California Health Care System   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ANTIBIOTIC AGENT; ISOTRETINOIN; METHOTREXATE; MYCOPHENOLIC ACID; USTEKINUMAB;

ABSCESS; ADULT; AXILLA; CASE REPORT; DISEASE EXACERBATION; DRUG DOSE INCREASE; EPIDERMOID CYST; HUMAN; INGUINAL REGION; LETTER; MALE; PRIORITY JOURNAL; PSORIASIS; PSORIASIS SEVERITY INDEX; QUALITY OF LIFE; SUPPURATIVE HIDRADENITIS; TREATMENT FAILURE; TREATMENT RESPONSE;

ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; DRUG RESISTANCE; HIDRADENITIS SUPPURATIVA; HUMANS; MALE; MIDDLE AGED; PSORIASIS;

EID: 84859738806     PISSN: 00015555     EISSN: None     Source Type: Journal    
DOI: 10.2340/00015555-1229     Document Type: Letter

References (12)

1. Sartorius K, Lapins J, Emtestam L, Jemec GB. Suggestions for uniform outcome variables when reporting treatment effects in hidradenitis suppurativa. Br J Dermatol 2003; 149: 211-213.
2. Grant A, Gonzalez T, Montgomery MO, Cardenas V, Kerdel FA. Infliximab therapy for patients with moderate to severe hidradenitis suppurativa: a randomized, doubleblind, placebo-controlled crossover trial. J Am Acad Dermatol 2010; 62: 205-217.
3. Poulin Y. Successful treatment of hidradenitis suppurativa with infliximab in a patient who failed to respond to etanercept. J Cutan Med Surg 2009; 13: 221-225.
4. Hunger RE, Surovy AM, Hassan AS, Braathen LR, Yawalkar N. Toll-like receptor 2 is highly expressed in lesions of acne inversa and colocalizes with C-type lectin receptor. Br J Dermatol 2008; 158: 691-697.
5. Griffiths CE, Strober BE, van de Kerkhof P, Ho V, Fidelus-Gort R, Yeilding N, et al. Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. N Engl J Med 2010; 362: 118-128.
6. Korn T, Bettelli E, Oukka M, Kuchroo VK. IL-17 and Th17 cells. Ann Rev Immunol 2009; 27: 485-517.
7. Ye P, Rodriguez FH, Kanaly S, Stocking KL, Schurr J, Schwarzenberger P, et al. Requirement of interleukin 17 receptor signaling for lung CXC chemokine and granulocyte colony-stimulating factor expression, neutrophil recruitment, and host defense. J Exp Med 2001; 194: 519-527.
8. Matusiak L, Bieniek A, Szepietowski JC. Increased serum tumour necrosis factor-alpha in hidradenitis suppurativa patients: is there a basis for treatment with anti-tumour necrosis factor-alpha agents? Acta Derm Venereol 2009; 89: 601-603.
9. Wolk K, Warszawska K, Hoeflich C, Witte E, Schneider-Burrus S, Witte K, et al. Deficiency of IL-22 contributes to a chronic inflammatory disease: pathogenetic mechanisms in acne inversa. J Immunol 2011; 186: 1228-1239.
10. Cua DJ, Sherlock J, Chen Y, Murphy CA, Joyce B, Seymour B, et al. Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. Nature 2003; 421: 744-748.
11. Alikhan A, Lynch PJ, Eisen DB. Hidradenitis suppurativa: a comprehensive review. J Am Acad Dermatol 2009; 60: 539-561; quiz 562-533.
12. Matusiak L, Bieniek A, Szepietowski JC. Hidradenitis suppurativa and associated factors: still unsolved problems. J Am Acad Dermatol 2009; 61: 362-365.